Cargando…

MPL exon 10 mutations in Irish patients with a suspected myeloproliferative neoplasm

Detalles Bibliográficos
Autores principales:	Lee Tokar, Lisa, Kearney, Laura, Langabeer, Stephen E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Leibniz Research Centre for Working Environment and Human Factors 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898040/ https://www.ncbi.nlm.nih.gov/pubmed/33628158 http://dx.doi.org/10.17179/excli2021-3454

Ejemplares similares

CALR mutations in myeloproliferative neoplasms: An unfolding story
por: Langabeer, Stephen E.
Publicado: (2020)

Concurrent chronic myeloid leukemia and CALR-mutated myeloproliferative neoplasm
por: Langabeer, Stephen E.
Publicado: (2020)

Hypercalcemia as a biomarker of myeloproliferative neoplasms?
por: Langabeer, Stephen E.
Publicado: (2019)

Dual Drivers in the Myeloproliferative Neoplasms: An Underestimation?
por: Langabeer, Stephen E.
Publicado: (2023)

Two activating mutations of MPL in triple‐negative myeloproliferative neoplasms
por: Xie, Juan, et al.
Publicado: (2019)

Molecular screening for an underlying myeloproliferative neoplasm in patients with stroke: who and how?
por: Langabeer, Stephen E.
Publicado: (2020)

CALR mutation analysis is not indicated in patients with splanchnic vein thrombosis without evidence of a myeloproliferative neoplasm: a micro-review
por: Langabeer, Stephen E.
Publicado: (2016)

MPL W515L/K Mutations in Chronic Myeloproliferative Neoplasms
por: Akpınar, Timur Selçuk, et al.
Publicado: (2013)

JAK2 exon 12 mutation-positive myeloproliferative neoplasm associated with recurrent thromboembolism
por: Tavakoli, Vahid, et al.
Publicado: (2017)

Molecular screening for an underlying myeloproliferative neoplasm in rheumatology patients
por: Langabeer, Stephen
Publicado: (2022)

Prefibrotic Myelofibrosis Presenting with Multiple Cerebral Embolic Infarcts and the Rare MPL W515S Mutation
por: Langabeer, Stephen E., et al.
Publicado: (2020)

Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms
por: Ha, Jung-Sook, et al.
Publicado: (2015)

Effects of Mutational Combinations on Philadelphia-Negative Myeloproliferative Neoplasms
por: Ipek, Yonal-Hindilerden, et al.
Publicado: (2017)

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
por: Li, Bing, et al.
Publicado: (2017)

Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms
por: Brecqueville, M, et al.
Publicado: (2011)

Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing
por: Thompson, Ella R., et al.
Publicado: (2020)

Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes
por: Brecqueville, M, et al.
Publicado: (2011)

Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms
por: Machado-Neto, João Agostinho, et al.
Publicado: (2015)

Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia
por: Morrell, Ruth, et al.
Publicado: (2013)

Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms
por: Singdong, Roongrudee, et al.
Publicado: (2016)

Reduction in molecular diagnostics of myeloproliferative neoplasms during the COVID-19 pandemic
por: Langabeer, Stephen E.
Publicado: (2020)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience
por: Begna, K, et al.
Publicado: (2016)

Molecular Diagnostics with Laboratory Finding in Patients with Myeloproliferative Neoplasms
por: MAKANI, Zahra, et al.
Publicado: (2017)

The role of the Exon 13 G571S JAK2 mutation in myeloproliferative neoplasms
por: Bahar, Burak, et al.
Publicado: (2016)

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients
por: Cassinat, Bruno, et al.
Publicado: (2020)

Correlation analysis between JAK2, MPL, and CALR mutations in patients with myeloproliferative neoplasms of Chinese Uygur and Han nationality and their clinical characteristics
por: Lang, Tao, et al.
Publicado: (2018)

JAK2, CALR, and MPL Mutation Profiles in BCR-ABL Negative Myeloproliferative Neoplasms, a Referral Center Experience in the Middle East
por: Safavi, Moeinadin, et al.
Publicado: (2021)

Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN)
por: Zulkeflee, Razan Hayati, et al.
Publicado: (2021)

Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms
por: Wiriyaukaradecha, Kriangpol, et al.
Publicado: (2022)

Mutational Analysis of SH2B3 in Korean Patients With BCR-ABL1 Negative Myeloproliferative Neoplasm
por: Kim, Namhee, et al.
Publicado: (2016)

Nontraumatic acute subdural hematoma associated with the myelodysplastic/myeloproliferative neoplasms
por: Ichimura, Shinya, et al.
Publicado: (2012)

The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms
por: de Freitas, Renata Mendes, et al.
Publicado: (2013)

Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches
por: Haslam, Karl, et al.
Publicado: (2016)

MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia
por: Haider, M, et al.
Publicado: (2016)

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
por: Tefferi, A
Publicado: (2010)

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL
por: Wang, Yan, et al.
Publicado: (2023)

Screening for an underlying myeloproliferative neoplasm in patients with thrombocytosis post-induction chemotherapy for acute myeloid leukemia
por: Langabeer, Stephen E.
Publicado: (2020)

SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms
por: Borsani, Oscar, et al.
Publicado: (2023)

Low frequency of c-MPL gene mutations in Iranian patients with Philadelphia-negative myeloproliferative disorders
por: Ghotaslou, A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0ojgt9nar1107d7umor96p6h5j